[Problem] The purpose of the present invention is to provide a modified adenovirus having a cytocidal activity on a target cell and high safety.

[Solution] The present invention pertains to: a modified adenovirus which comprises an E1A gene, an enhancer sequence having a function of enhancing the expression of the E1A gene, and an AU-rich element introduced into the 3′-untranslated region of a viral gene, which is essentially required for the self-propagation thereof, or a position adjacent to the 3′-untranslated region, or a modified adenovirus which comprises an E1A gene and an enhancer sequence having a function of enhancing the expression of the E1A gene and cannot express normal E4orf6 protein, wherein the distance between the 5′-terminus of the E1A gene and the terminus of the enhancer sequence is 1500-4500 bp; and a medicine comprising the same.

This invention relates to a process for producing a library of viruses, comprising first and second culturing steps. These steps aim to promote intra-species and inter-species recombination, respectively, between double-stranded DNA viruses of the same virus family.

Synthetic adenoviruses having chimeric fiber proteins and liver detargeting mutations are described. The synthetic adenovirus vectors are capable of specifically infecting cells at wound sites or in regions of damaged tissue. The synthetic adenovirus vectors also are capable of expressing transgenes, such as wound healing factors, at sites of wounded or damaged tissue. Accordingly, the described vectors can be used to detect wounded or damaged tissue, and/or to promote wound healing and regeneration of damaged tissue, such as by expression of heterologous wound healing or tissue regeneration factors.

The present invention provides methods for treating an individual having solid or lymphatic tumor comprising local administration to the site of the tumor an infectious agent an immunomodulator (including a combination of immunomodulators). The methods may further comprise local administration to the site of the tumor inactivated tumor cells. Also provided are compositions and kits for the cancer therapy methods.

Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor by inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.

The present invention relates to a composition for enhancing oncolytic virus activity which comprises nc886, and a composition for enhancing virus production which comprises the same.

This invention relates to methods and materials for nucleic acid delivery, vaccination, and/or treating cancer. More specifically, methods and materials for nucleic acid delivery, vaccination, and/or treating cancer using one or more recombinant adenoviruses (Ads) as an oncolytic agent are provided.

A method of treating a human patient comprising systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1×10.sup.10 to 1×10.sup.14 viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 2×10.sup.10 particles per minute to 2×10.sup.12 particles per minute. Also provided are formulations of the oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.

The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.